Zacks Investment Research upgraded shares of NXSTAGE MEDICAL (NXTM) from NEUTRAL to OUTPERFORM on January 10, 2013, with a target price of $14.00.
NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NXSTAGE MEDICAL (NXTM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment